API TB Consensus Guidelines 2006: Management of Pulmonary Tuberculosis, Extra-Pulmonary Tuberculosis and Tuberculosis in Special Situations

EXECUTIVE SUMMARY

The World Health Organization (WHO) has declared Tuberculosis (TB) a global emergency in 1993. Prevalence of TB and Human Immunodeficiency Virus (HIV) co-infection worldwide is 0.18% and about 8% TB cases have HIV infection. Effective chemotherapy has been available for treatment of TB for over 50 years now. In World Health Organization (WHO)–International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group Global Anti-Tuberculosis Drug Resistance Surveillance (1994-1997), the incidence of MDR TB in Delhi was found to be 14%, of which primary multi-drug resistance was only 1.4%, indicating that most of MDR TB is acquired as a result of poor chemotherapy.

API Consensus Expert Committee

JM Joshi, Professor and Head, Department of Respiratory Medicine, B. Y. L. Nair Hospital, Mumbai, India. VK Vijayan, Director, Vallabhbhai Patel Chest Institute, Editor-in-Chief of Indian Journal of Chest Diseases and Allied Sciences and Ex-Senior Deputy Director, Tuberculosis Research Centre, Chennai, India; SK Jindal, Professor and Head, Dept of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, Editor-in Chief, Lung, India; K Jagganath, Pulmonary Consultant, Chennai Research Institute, Chennai and Ex- director of Institute of Thoracic Medicine, Chetput, Chennai, India; Camilla Rodrigues, Consultant Microbiologist, PD Hinduja Hospital, Mumbai, India; SB Gupta, Consultant Physician and Cardiologist, Baba Saheb Ambedkar Memorial Hospital, Byculla, Mumbai and Past President of API, India.

Address for correspondence: JM Joshi, Professor and Head, Department of Respiratory Medicine, B. Y. L. Nair Hospital, Mumbai, India.

‘For Full Text kindly contact on japi@bom5.vsnl.net.in/srjoshi@vsnl.com quoting your API membership number’.